Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports

Yoshino, K; Nakayama, T; Ito, A; Sato, E; Kitano, S

Yoshino, K (reprint author), Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Dermato Oncol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138677, Japan.; Kitano, S (reprint author), Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan.

BMC CANCER, 2019; 19 (1):

Abstract

Background: Nivolumab is an immune checkpoint inhibitor specific to the programmed death 1 (PD-1) receptor. Nivolumab has shown clinical responses in ......

Full Text Link